Participants
bleeding, Down Syndrome, psychiatric, trisomies, abortion
MOLAR PREGNANCY, BLEEDING, DOWN SYNDROME, COMPLICATIONS OF PREGNANCY, MISCARRIAGE, TRISOMIES
Based on the mean and standard deviation of worry scores in the intervention (24.18 ± 8.03) and control (17.55 ± 5.06) groups in the Kordi et al. study [During the initial antenatal visit, women are provided with verbal information regarding prenatal screening. Subsequently, after becoming acquainted with the details, informed consent is obtained from women regarding their decision to participate or decline the first trimester fetal abnormality screening test. The appropriate test for Iranian society should be performed in the first trimester so that there is a possibility of therapeutic abortion if there is an abnormality. Due to the prevailing religious and legal conditions in our country, medical abortion is permitted only up to 19th gestational weeks based on the LMP. Screening test for detecting 21, 13, and 18 trisomies in the first trimester of pregnancy includes Pregnancy Associated Plasma Protein A (A-PAPP), Beta - human chorionic gonadotrophin (FBHCG) and Fetal Nuchal Translucency (NT). Patients are divided into three categories: high risk (risk greater than 1:50), medium risk (between 1:51 − 1:1500) and low risk (risk less than 1:1501).Inclusion criteria included pregnant women with intermediate risk (1: 51 − 1:1500) during first-trimester screening for Down Syndrome and without additional structural anomalies, willingness to participate in the study, literate, and gestational age less than 14 weeks. Exclusion criteria before allocation into two groups included unwillingness to continue the study, having a physical and mental illness or use of psychiatric medications, complications of pregnancy such as bleeding and suspected miscarriage, and molar pregnancy.